

Human 4-1BB Ligand/TNFSF9 PE-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 282220

Catalog Number: FAB2295P 100 TESTS


DESCRIPTION		
Species Reactivity	Human	
Specificity	Detects human 4-1BB Ligand/TNFSF9 in direct ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant mouse (rn 4-1BB Ligand, recobinant human (rh) APRIL, rhBAFF, rmEDA-A2, rhFas Ligand, rhGITR Ligand, rhLIGHT, rhLymphotoxin α1/β2, rhLymphotoxin α2/β1, rhOX40 Ligand, rhTNF-α, rhTRAIL, rhTRANCE, or rhTWEAK is observed.	
Source	Monoclonal Mouse IgG _{2B} Clone # 282220	
Purification	Protein A or G purified from hybridoma culture supernatant	
Immunogen	<i>E. coli</i> -derived recombinant human 4-1BB Ligand/TNFSF9 Arg71-Glu254 Accession # P41273.1	
Conjugate	Phycoerythrin Excitation Wavelength: 488 nm Emission Wavelength: 565-605 nm	
Formulation	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.	
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	10 μL/10 ⁶ cells	See Below

DATA



Detection of 4-1BB Ligand/TNFSF9 in Raji Human Cell Line by Flow Cytometry. Raji human Burkitt's lymphoma cell line was stained with Mouse Anti-Human 4-1BB Ligand/TNFSF9 PE-conjugated Monoclonal Antibody (Catalog # FAB2295P, filled histogram) or isotype control antibody (Catalog # IC0041P, open histogram). View our protocol for Staining Membrane-associated Proteins.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze.

• 12 months from date of receipt, 2 to 8 °C as supplied.





Human 4-1BB Ligand/TNFSF9 PE-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 282220

Catalog Number: FAB2295P 100 TESTS

BACKGROUND

4-1BB Ligand (4-1BBL; also CD137L) is a 32 kDa type II transmembrane protein that belongs to the TNF superfamily (TNFSF) of molecules (1-4). The human 4-1BBL cDNA encodes a 254 amino acid (aa) protein that contains a 25 aa N-terminal cytoplasmic domain, a 23 aa transmembrane segment, and a 206 aa C-terminal extracellular region (5). The extracellular domain (ECD) of 4-1BBL has a jelly-roll, β-sandwich tertiary structure that is similar to other TNFSF members. There is only one cysteine in the human ECD, and no potential N-linked glycosylation sites. The potential exists, however, for O-linked glycosylation. The human 4-1BBL ECD shares 32% and 35% aa identity with mouse and rat ECD, respectively. In the cytoplasmic domain, human 4-1BBL is 55 aa shorter than the equivalent region in rodents. 4-1BBL is expressed by activated B cells, macrophages, dendritic cells, activated T cells, neurons and astrocytes (2, 3, 6). A bioactive 26 kDa soluble form of 4-1BBL, presumably generated by MMP cleavage, occurs in humans (4). Human 4-1BBL signals through both CD137/4-1BB and itself. Its cytoplasmic tail participates in reverse signaling that induces apoptosis in T cells and cytokine secretion (IL-6; TNF-α) by monocytes (7, 8). 4-1BBL binding to CD137/4-1BB produces a number of effects. It seems to play a key role in the T cell recall response. It maintains T cell numbers at the end of a primary response, and induces CD4⁺ and CD8⁺ T cells to proliferate and secrete cytokines such as IL-2 and IFN-γ in CD4⁺ T cells, and IFN-γ in CD8⁺ T cells (9, 10).

References:

- 1. Kwon, B. et al. (2003) Exp. Mol. Med. 35:8
- 2. Salih, H.R. et al. (2002) Int. J. Clin. Pharmacol. Ther. 40:348.
- 3. Vinay, D.S. and B.S. Kwon (1998) Semin. Immunol. **10**:481.
- 4. Salih, H.R. et al. (2001) J. Immunol. 167:4059.
- Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
- 6. Reali, C. et al. (2003) J. Neurosci. Res. 74:67.
- 7. Michel, J. et al. (1999) Immunology 98:42.
- 8. Langstein, J. et al. (1998) J. Immunol. 160:2488.
- 9. Wen, T. et al. (2002) J. Immunol. 168:4897.
- 10. Dawicki, W. and T.H. Watts (2004) Eur. J. Immunol. 34:743.

